Exercise Tolerance in Patients With CABG and Sternotomy vs. Patients With Minimally Invasive Coronary Surgery (ENDO-ACAB)
Exercise Tolerance in Patients With Coronary Artery Bypass Surgery (CABG) and Sternotomy vs. Patients With Minimally Invasive Coronary Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Hasselt, Belgium, 3500
- Jessa Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- undergoing this type of surgery. For healthy subjects: must be sedentary.
Exclusion Criteria:
- any neurologic, nephrologic, respiratory disease. For healthy subjects: any chronic disease or condition.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
healthy individuals
Age, gender and BMI matched healthy subjects without any chronic disease or physical disability, and being sedentary.
|
Maximal exercise test with ergospirometry.
|
|
CABG patients
Age, gender and BMI matched CABG patients, without neurologic, nephrologic, respiratory disease.
|
Maximal exercise test with ergospirometry.
|
|
endo-ACAB patients
Age, gender and BMI matched endo-ACAB patients without neurologic, nephrologic, respiratory disease.
|
Maximal exercise test with ergospirometry.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VO2peak (peak oxygen uptake)
Time Frame: At peak exercise, single measurement which is executed between 2-4 weeks after surgery.
|
Peak oxygen uptake capacity, expressed as ml/min.
|
At peak exercise, single measurement which is executed between 2-4 weeks after surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Paul Dendale, Jessa Hospital, Stadsomvaart 11, 3500 Hasselt, Belgium
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- ENDO-ACAB study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Bypass Surgery
-
NCT06602336RecruitingCoronary Artery Bypass | CABG | Valve Surgery | Coronary Artery Bypass Graft | Cardiovascular | Valve Replacement | Coronary Artery Bypass Graft Surgery (CABG)
-
NCT01386229UnknownCoronary Artery Bypass Surgery
-
NCT01098409UnknownCoronary Artery Bypass Surgery
-
NCT00073593CompletedCardiac Surgery | Coronary Artery Bypass Surgery
-
NCT05411445Recruiting
-
NCT05396690Not yet recruitingCoronary Artery Bypass Surgery
-
NCT00670176Completed
-
NCT02105610CompletedCardiac Surgery | Coronary Artery Bypass Grafting | Aortocoronary Bypass
-
NCT00964015TerminatedCoronary Artery Bypass Surgery
-
NCT00244283UnknownCoronary Artery Bypass Surgery
Clinical Trials on Cardiopulmonary exercise test
-
NCT05413876RecruitingFabry Disease | Fabry Disease, Cardiac Variant
-
NCT03993522TerminatedCoronary Occlusion
-
NCT01900600CompletedPrior Acute Myocardial Infarction | Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l) | Reduced Left Ventricle Ejection Fraction (<50%) | Symptoms of Heart Failure (NYHA Class II-III)
-
NCT03215459Not yet recruiting
-
NCT06400212CompletedInflammatory Response | Immune System
-
NCT04451681CompletedAnkylosing Spondylitis
-
NCT04141345CompletedComorbid Chronic Lung Disease on Heart Failure
-
NCT02636452CompletedInterstitial Lung Disease
-
NCT02436213CompletedHereditary Hemorrhagic Telangiectasia | Pulmonary Arteriovenous Malformations